Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

A new oral weight loss pill shows results similar to Ozempic and Wegovy injections in the treatment of obesity.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Eli Lilly’s orforglipron pill, licensed from Chugai Pharmaceutical, could reshape the booming weight-loss drug market, early ...

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...